Primary endpoint IS the primary endpoint. The OS an issue because it is compared to the ECA that was ginned up by NWBO's consultants right before the datalock NOT before the clinical trial began as required by FDA Guidelines. PFS is a commonly used endpoint for oncology trials. Just because you don't like those results doesn't mean you can toss it out. That's not how trials work.
The direct evidence is clear -- NWBO DIDN'T FILE AN APPLICATION WITH THE FDA. NO MORE EVIDENCE REQUIRED -- AND IT HAS NOW BEEN OVER 2 YEARS AND THEY STILL HAVEN'T FILED WITH THE FDA.
Market Data 
Markets 
